Last reviewed · How we verify
Magnesium sulfate 33% solution
Magnesium sulfate 33% solution is a Electrolyte supplement / anticonvulsant Small molecule drug developed by The Baruch Padeh Medical Center, Poriya. It is currently FDA-approved for Seizure prophylaxis and treatment in pre-eclampsia and eclampsia, Acute asthma exacerbation (bronchodilation), Cardiac arrhythmias (particularly torsades de pointes).
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and smooth muscle contractility.
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuromuscular excitability and vascular smooth muscle contractility. Used for Seizure prophylaxis in preeclampsia and eclampsia, Preterm labor management, Hypertensive emergency.
At a glance
| Generic name | Magnesium sulfate 33% solution |
|---|---|
| Sponsor | The Baruch Padeh Medical Center, Poriya |
| Drug class | Electrolyte supplement / anticonvulsant |
| Target | Voltage-gated calcium channels, NMDA receptors |
| Modality | Small molecule |
| Therapeutic area | Obstetrics, Neurology, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Magnesium ions compete with calcium for binding sites on voltage-gated calcium channels and block NMDA-type glutamate receptors, thereby decreasing cellular excitability. This mechanism underlies its use in preventing seizures (particularly eclampsia/pre-eclampsia), treating cardiac arrhythmias, and providing bronchodilation in acute asthma. The 33% solution provides a concentrated form for parenteral administration.
Approved indications
- Seizure prophylaxis and treatment in pre-eclampsia and eclampsia
- Acute asthma exacerbation (bronchodilation)
- Cardiac arrhythmias (particularly torsades de pointes)
- Magnesium deficiency (hypomagnesemia)
- Constipation (as laxative)
Common side effects
- Flushing and warmth sensation
- Hypotension
- Muscle weakness
- Respiratory depression (at high doses)
- Hypermagnesemia
- Loss of deep tendon reflexes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium sulfate 33% solution CI brief — competitive landscape report
- Magnesium sulfate 33% solution updates RSS · CI watch RSS
- The Baruch Padeh Medical Center, Poriya portfolio CI
Frequently asked questions about Magnesium sulfate 33% solution
What is Magnesium sulfate 33% solution?
How does Magnesium sulfate 33% solution work?
What is Magnesium sulfate 33% solution used for?
Who makes Magnesium sulfate 33% solution?
What drug class is Magnesium sulfate 33% solution in?
What development phase is Magnesium sulfate 33% solution in?
What are the side effects of Magnesium sulfate 33% solution?
What does Magnesium sulfate 33% solution target?
Related
- Drug class: All Electrolyte supplement / anticonvulsant drugs
- Target: All drugs targeting Voltage-gated calcium channels, NMDA receptors
- Manufacturer: The Baruch Padeh Medical Center, Poriya — full pipeline
- Therapeutic area: All drugs in Obstetrics, Neurology, Cardiovascular
- Indication: Drugs for Seizure prophylaxis and treatment in pre-eclampsia and eclampsia
- Indication: Drugs for Acute asthma exacerbation (bronchodilation)
- Indication: Drugs for Cardiac arrhythmias (particularly torsades de pointes)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing